EMCOP联合化疗治疗非何杰金淋巴瘤疗效观察

应用EMCOP联合化疗方案（VP16、MX、CTX、VCR、pred）治疗非何杰金淋巴瘤（non-Hodgkin’slymphoma，NHL）患者33例。其中初治19例、难治性4例、复发10例。结果：19例初治患者CR率为68．4％，PR率为15．8％，总缓解率为84．2％；14例复发和难治性NHL患者，CR率为28．6％、PR率为42．8％。提示本方案为治疗NHL较理想的化疗方案，无论初治或复发与难治性NHL患者，均有较高的缓解率。作者并对疗效、毒副反应以及药物剂量与缓解的关系作了讨论。

The Effectiveness of EMCOP in Treating Malignant NHL

In this paper the effectiveness of EMCOP chemotherapy was studied. Thirty three Pts with malignant non- Hodgkin's lymphoma (NHL) were treated with a combination chemotherapy of EMCOP (etoposide, mitoxantrone, cyclophosphamide, vincristine and prednisone). Nineteen Pts with newly diagnosed NHL were treated, CR was obtained in 13 (68.4%) cases and PR in 3(15.8%) cases with an overall response of 84.2%; 4 Pts(28.6%) in fourteen Pts with refractory or relapsed disease obtained CR and 6 cases PR. In this paper the side - effect of EMCOP was also discussed.